1. Townsend CM Jr, Beauchamp RD, Evers BM, Mattox KL. Sabiston Textbook of Surgery: the Biological Basis of Modern Surgical Practice. 20th ed. Philadelphia (PA): Elsevier Saunders;2017.
2. Korea Central Cancer Registry. National Cancer Center (KR). Ministry of Health and Welfare (KR). Annual Report of Cancer Statistics in Korea in 2015. Goyang: Korea Central Cancer Registry;2017.
3. Lloyd RV, Osamura RY, Klöppel G, Rosai J. World Health Organization. International Agency for Research on Cancer. WHO Classification of Tumours of Endocrine Organs. 4th ed. Lyon: International Agency for Research on Cancer;2017.
4. Al-Kurd A, Mekel M, Mazeh H. Parathyroid carcinoma. Surg Oncol. 2014; 23:107–114.
5. Owen RP, Silver CE, Pellitteri PK, Shaha AR, Devaney KO, Werner JA, et al. Parathyroid carcinoma: a review. Head Neck. 2011; 33:429–436.
6. Talat N, Schulte KM. Clinical presentation, staging and long-term evolution of parathyroid cancer. Ann Surg Oncol. 2010; 17:2156–2174.
7. Schulte KM, Talat N, Galata G, Gilbert J, Miell J, Hofbauer LC, et al. Oncologic resection achieving R0 margins improves disease-free survival in parathyroid cancer. Ann Surg Oncol. 2014; 21:1891–1897.
8. Givi B, Shah JP. Parathyroid carcinoma. Clin Oncol (R Coll Radiol). 2010; 22:498–507.
9. Ricci G, Assenza M, Barreca M, Liotta G, Paganelli L, Serao A, et al. Parathyroid carcinoma: the importance of high clinical suspicion for a correct management. Int J Surg Oncol. 2012; 2012:649148.
10. Shane E. Clinical review 122: parathyroid carcinoma. J Clin Endocrinol Metab. 2001; 86:485–493.
11. Kassahun WT, Jonas S. Focus on parathyroid carcinoma. Int J Surg. 2011; 9:13–19.
12. Duan K, Mete Ö. Parathyroid carcinoma: diagnosis and clinical implications. Turk Patoloji Derg. 2015; 31:Suppl 1. 80–97.
13. Kim BS, Ryu HS, Kang KH, Park SJ. Parathyroid carcinoma in tertiary hyperparathyroidism. Asian J Surg. 2016; 39:255–259.
14. Takada D, Tsukamoto T, Fuse M, Kada S, Yanagita M. The use of cinacalcet hinders the diagnosis of parathyroid carcinoma in a chronic dialysis patient: a case report. BMC Nephrol. 2017; 18:315.
15. Bossola M, Tazza L, Ferrante A, Giungi S, Carbone A, Gui D, et al. Parathyroid carcinoma in a chronic hemodialysis patient: case report and review of the literature. Tumori. 2005; 91:558–562.
16. Falvo L, Catania A, Palermo S, Sorrenti S, Bonifazi AP, De Stefano M, et al. Bilateral synchronous parathyroid carcinoma in a patient on long-term hemodialysis: presentation of a rare clinical case and review literature. Int Surg. 2005; 90:18–22.
17. Zivaljevic V, Krgovic K, Tatic S, Havelka M, Dimitrijevic Z, Diklic A, et al. Parathyroid cancer in a hemodialysis patient: a case report. Tumori. 2002; 88:430–432.
18. Bondeson L, Sandelin K, Grimelius L. Histopathological variables and DNA cytometry in parathyroid carcinoma. Am J Surg Pathol. 1993; 17:820–829.
19. Snover DC, Foucar K. Mitotic activity in benign parathyroid disease. Am J Clin Pathol. 1981; 75:345–347.
20. Ippolito G, Palazzo FF, Sebag F, De Micco C, Henry JF. Intraoperative diagnosis and treatment of parathyroid cancer and atypical parathyroid adenoma. Br J Surg. 2007; 94:566–570.
21. DeLellis RA. Parathyroid tumors and related disorders. Mod Pathol. 2011; 24:Suppl 2. S78–S93.
22. Stojadinovic A, Hoos A, Nissan A, Dudas ME, Cordon-Cardo C, Shaha AR, et al. Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis. Hum Pathol. 2003; 34:54–64.
23. Fernandez-Ranvier GG, Khanafshar E, Tacha D, Wong M, Kebebew E, Duh QY, et al. Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer. 2009; 115:334–344.
24. Baek CO, Kim KH, Song SK. Synchronous parathyroid carcinoma and papillary thyroid carcinoma in a patient with long-standing schizophrenia. Korean J Intern Med. 2017; 32:1104–1107.
25. Chaychi L, Belbruno K, Golding A, Memoli V. Unusual manifestation of parathyroid carcinoma in the setting of papillary thyroid cancer. Endocr Pract. 2010; 16:664–668.
26. Savli H, Sevinc A, Sari R, Ozen S, Buyukberber S, Ertas E. Occult parathyroid carcinoma in a patient with papillary thyroid carcinoma and Hashimoto's thyroiditis. J Endocrinol Invest. 2001; 24:42–44.
27. Kim JK, Chai YJ, Chung JK, Hwang KT, Heo SC, Kim SJ, et al. The prevalence of primary hyperparathyroidism in Korea: a population-based analysis from patient medical records. Ann Surg Treat Res. 2018; 94:235–239.
28. Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993–2001: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006; 21:171–177.
29. Adami S, Marcocci C, Gatti D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res. 2002; 17:Suppl 2. N18–N23.
30. Yu N, Donnan PT, Murphy MJ, Leese GP. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clin Endocrinol (Oxf). 2009; 71:485–493.